FCMI
PRQR icon

Foresite Capital Management II’s ProQR Therapeutics PRQR Stock Holding History

Foresite Capital Management II’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-173,067
Closed -$3.75M – 17
2014
Q4 		$3.75M Buy
+173,067
New +$2.63M 2.57% 14

Other funds holding PRQR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Foresite Capital Management II's PRQR Position: Q1 2015 in Review

Foresite Capital Management II sold out of ProQR Therapeutics (PRQR) in Q1 2015, closing a stake of 173,067 shares — an estimated $3.75M sold.

Foresite Capital Management II first reported a position in PRQR in Q4 2014 and held it in 1 quarter. The position peaked at $3.75M in Q4 2014. 38 funds tracked by Wall St. Rank hold PRQR as of Q1 2015.

  • Foresite Capital Management II reported no remaining ProQR Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Foresite Capital Management II sold 173,067 ProQR Therapeutics shares in Q1 2015, an estimated $3.75M.
  • Foresite Capital Management II first reported a position in ProQR Therapeutics in Q4 2014 and held it in 1 quarter.
  • Foresite Capital Management II's ProQR Therapeutics position peaked at $3.75M in Q4 2014.
  • 38 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2015.

Based on Foresite Capital Management II's 13F filing for Q1 2015, filed 5 May 2015.